Is an evolution of sorts happening within advanced visualization?

January 14, 2009 - According to Millennium Research Group's (MRG's) U.S. Markets for Electrophysiology (EP) Mapping and Ablation Devices 2009 report, an increase in the number of catheter ablation procedures for treating atrial fibrillation (AF) will fuel revenues in the EP ablation catheter market over the next five years.

The ablation catheter market will exhibit strong growth from 2008 to 2013, at a compound annual rate of almost 14 percent, exceeding $480 million by the end of 2013, MRG said.

January 14, 2009 - Society of Nuclear (SNM) will devote its annual Molecular Imaging Summit to introducing the new SNM Clinical Trials Network, Feb. 8–9, at the Hilton Clearwater Hotel, Clearwater, FL.

In part, the program will explain requirements of participation in the Clinical Trials Network, which was designed to facilitate cost-effective drug development through the integration of imaging biomarkers into phase 1, 2, 3 and 4 therapeutics clinical trials. In addition, the workshop will explore key issues involved with imaging participation in multi-center trials.

January 14, 2009 - University of Ottawa Heart Institute (UOHI) researchers have successfully grown blood vessels in damaged muscle tissue by injecting a biomaterial developed specifically to attract new cells and support regeneration.

Blood vessel regeneration suggests that the body's own cells might one day be used to repair heart damage and restore function.

Details of the regeneration process are published online in the Journal of the Federation of American Societies for Experimental Biology (http://www.fasebj.org/cgi/content/abstract/fj.08-111054v1).

January 13, 2009 - Vital Images Inc. and Toshiba Medical Systems Corp. have agreed to collaborate on a joint investment to develop and deliver innovative technology advancements for Toshiba's modalities, including the Aquilion ONE CT scanner, and Vital Images' advanced visualization software solutions.

January 13, 2009 -W.L. Gore and Associates today said it received CE Mark of its GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface in the European Union.

The GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface combines Gore’s propriety heparin surface with the performance of the GORE VIABAHN Endoprosthesis for the treatment of arterial vascular disease. The GORE VIABAHN Endoprosthesis is indicated for the endovascular grafting of peripheral arteries.

January 13, 2009 - Edwards Lifesciences Corp. said Jan. 9 the Patents Court in the United Kingdom upheld the validity of Edwards’ U.K. Andersen patent for transcatheter valve technology and had CoreValve Inc.’s invalidity claims dismissed on all grounds.

January 13, 2009 - Stereotaxis Inc. said the first crossing of a chronic total occlusion (CTO) using the RF PowerAssert Magnetic Guide Wire was undertaken by Austin Heart interventional cardiologist Frank Zidar, M.D. Jan. 7, on a patient with severe peripheral artery disease (PAD).

Cleared by the FDA in 2008, the RF PowerAssert guide wire is the only magnetically enabled device available for crossing peripheral occlusions, including CTOs. Used with the Niobe Magnetic Navigation System, it is an innovative solution that enables precise intra-lesion control of its distal tip.

January 13, 2009 - Michigan CardioVascular Institute (MCVI), a twenty-two location cardiovascular group practice based in Saginaw, selected the integrated Sage Intergy practice management (PM) and Sage Intergy EHR electronic health records system to improve care, workflow, data access and reporting.

The group, which includes 33 nationally recognized cardiologists and heart surgeons and employs more than 260 people at 22 locations in mid Michigan, also wants to standardize care and prepare for a pay-for-performance environment.

January 13, 2009 - Micell Technologies, a development-stage biomedical device company dedicated to developing innovative interventional cardiology systems, has obtained the rights to Maxcor's CE-marked Genius MAGIC Cobalt Chromium Coronary Stent System for the purpose of developing and marketing drug-eluting stents (DES) based on Micell's prop coating technology.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now